论文部分内容阅读
目的 :探讨nm23基因在临床I期乳腺癌中的表达情况及其与预后、转移的关系。方法 :应用免疫组化方法 ,对112例原发I期乳腺癌病例进行了nm23蛋白表达的检测 ,并进行回顾性研究。结果 :(1)在112例中 ,nm23低表达组为50例 (44 64 % ) ,高表达组为62例 (55 36 % )。(2)nm23基因高表达组患者的15年无病生存率显著高于低表达组 (P<0.05)。 (3)腋淋巴结阴性者中 ,nm23基因高表达组患者的15年无病生存率亦明显高于低表达组(P<0.01)。结论 :在I期乳腺癌中 ,nm23基因表达水平对评估预后的远期疗效起一定作用 ,并提示临床工作者应对腋淋巴结阴性病例中的nm23基因低表达者予以重视 ,以进一步提高I期乳腺癌的治疗水平
Objective: To investigate the expression of nm23 gene in clinical stage I breast cancer and its relationship with prognosis and metastasis. Methods: Immunohistochemistry was used to detect the expression of nm23 protein in 112 cases of primary stage I breast cancer, and retrospectively studied. Results: (1) In 112 cases, nm23 low expression group was 50 cases (44 64%), high expression group was 62 cases (55 36%). (2) The 15-year disease-free survival rate of patients with high expression of nm23 gene was significantly higher than that of low expression group (P <0.05). (3) In axillary lymph node negative patients, the 15-year disease-free survival rate of patients with high expression of nm23 gene was also significantly higher than that of low expression group (P <0.01). Conclusion: In stage I breast cancer, the expression of nm23 gene may play a role in the long-term evaluation of prognosis, and prompt clinicians to pay attention to the low expression of nm23 gene in axillary lymph node negative cases to further improve stage I breast Cancer treatment level